MARKET

SBBP

SBBP

Strongbridge
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.130
+0.090
+2.96%
After Hours: 3.120 -0.01 -0.32% 17:14 01/24 EST
OPEN
3.060
PREV CLOSE
3.040
HIGH
3.140
LOW
3.060
VOLUME
486.41K
TURNOVER
--
52 WEEK HIGH
5.69
52 WEEK LOW
1.430
MARKET CAP
169.66M
P/E (TTM)
3.318
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SBBP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SBBP News

  • Strongbridge Bio sees Keveyis net sales for FY 2019 as high as $21.7M
  • Seeking Alpha - Article.01/09 14:33
  • Strongbridge Biopharma Sees Q4 KEVEYIS Sales ~$5.6M; FY19 Sales ~$21.7M; Sees FY20 Sales ~$26M-$27M
  • Benzinga.01/09 12:34
  • Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2019 Financial Results and Provides Update on Corporate Priorities
  • GlobeNewswire.01/09 12:30
  • Should You Avoid Strongbridge Biopharma plc (SBBP)?
  • Insider Monkey.12/16/2019 12:35

More

Industry

Pharmaceuticals
-1.84%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About SBBP

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
More

Webull offers Strongbridge Biopharma plc (SBBP) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.